An update on the multimodality of localized rectal cancer

被引：4

作者：

Artac, Mehmet ^{[1
]}

Korkmaz, Levent ^{[1
]}

El-Rayes, Bassel ^{[2
]}

Philip, Philip A. ^{[3
]}

机构：

[1] Necmettin Erbakan Univ, Meram Med Fac, Dept Med Oncol, Konya, Turkey

[2] Emory Univ, Winship Canc Inst, Dept Med Oncol, Atlanta, GA 30322 USA

[3] Karmanos Canc Ctr, Dept Gastrointestinal Oncol, Detroit, MI USA

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2016年 / 108卷

关键词：

Rectal cancer; Locally advanced; Neo-adjuvant; Surgery; Chemo-radiotherapy; PHASE-III TRIAL; POSTOPERATIVE ADJUVANT CHEMOTHERAPY; PATHOLOGICAL COMPLETE RESPONSE; TOTAL MESORECTAL EXCISION; SHORT-COURSE RADIOTHERAPY; WILD-TYPE KRAS; PREOPERATIVE RADIOTHERAPY; RADIATION-THERAPY; RANDOMIZED-TRIAL; NEOADJUVANT CHEMORADIOTHERAPY;

D O I：

10.1016/j.critrevonc.2016.10.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

New strategies have reduced the local recurrence (LR) rate and extended the duration of overall survival (OS) in patients with localized rectal cancer (RC) in recent decades. The mainstay of curative treatment remains radical surgery; however, downsizing the tumor by neo-adjuvant chemo-radiotherapy and adjuvant cytotoxic therapy for systemic disease has shown significant additional benefit. The standardization of total mesorectal excision (TME), radiation treatment (RT) dose and fractionation, and optimal timing and sequencing of treatment modalities with the use of prolonged administration of fluoropyrimidine concurrent with RT have significantly decreased the rates of LR in locally advanced rectal cancer (LARC) patients. This review focuses on the optimization of multi-modality therapies in patients with localized RC. (C) 2016 Elsevier Ireland Ltd. All rights reserved.

引用

页码：23 / 32

页数：10

共 94 条

[11]

BALSLEV IB, 1986, CANCER-AM CANCER SOC, V58, P22, DOI 10.1002/1097-0142(19860701)58:1<22::AID-CNCR2820580106>3.0.CO

[12]

2-Q

[13] Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer [J].

Bokemeyer, Carsten ;

Bondarenko, Igor ;

Makhson, Anatoly ;

Hartmann, Joerg T. ;

Aparicio, Jorge ;

de Braud, Filippo ;

Donea, Serban ;

Ludwig, Heinz ;

Schuch, Gunter ;

Stroh, Christopher ;

Loos, Anja H. ;

Zubel, Angela ;

Koralewski, Piotr .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :663-671

[14] Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study [J].

Bosset, Jean-Francois ;

Calais, Gilles ;

Mineur, Laurent ;

Maingon, Philippe ;

Stojanovic-Rundic, Suzana ;

Bensadoun, Rene-Jean ;

Bardet, Etienne ;

Beny, Alexander ;

Ollier, Jean-Claude ;

Bolla, Michel ;

Marchal, Dominique ;

Van Laethem, Jean-Luc ;

Klein, Vincent ;

Giralt, Jordi ;

Clavere, Pierre ;

Glanzmann, Christoph ;

Cellier, Patrice ;

Collette, Laurence .

LANCET ONCOLOGY, 2014, 15 (02) :184-190

[15]

Bosset Jean-Francois, 2008, Gastrointest Cancer Res, V2, P37

[16] Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer [J].

Bujko, K. ;

Nowacki, M. P. ;

Nasierowska-Guttmejer, A. ;

Michalski, W. ;

Bebenek, M. ;

Kryj, M. .

BRITISH JOURNAL OF SURGERY, 2006, 93 (10) :1215-1223

[17] Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: A meta-analysis of randomized trials comparing surgery ± a fluoropyrimidine and surgery plus a fluoropyrimidine ± oxaliplatin [J].

Bujko, K. ;

Glimelius, B. ;

Valentini, V. ;

Michalski, W. ;

Spalek, M. .

EJSO, 2015, 41 (06) :713-723

[18]

CASS AW, 1976, CANCER-AM CANCER SOC, V37, P2861, DOI 10.1002/1097-0142(197606)37:6<2861::AID-CNCR2820370643>3.0.CO

[19]

2-3

[20]

CEDERMARK B, 1995, CANCER-AM CANCER SOC, V75, P2269, DOI 10.1002/1097-0142(19950501)75:9<2269::AID-CNCR2820750913>3.0.CO

← 1 2 3 4 5 6 7 8 9 10 →